Clinical efficacy and safety of pemetrexed and nedaplatin in treatment of advanced lung adenocarcinoma

Yi ZHOU; Jian ZHOU; Ying ZHANG; Shengjie ZHONG; Jun YANG; Suping TAO

doi:10.16016/j.1000-5404.201801020

您当前的位置：

首页 >

文章列表页 >

Clinical efficacy and safety of pemetrexed and nedaplatin in treatment of advanced lung adenocarcinoma

Clinical Medicine | 更新时间：2026-01-09

- Clinical efficacy and safety of pemetrexed and nedaplatin in treatment of advanced lung adenocarcinoma
- Journal of Third Military Medical University Vol. 40, Issue 13, Pages: 1236-1241(2018)
- 作者机构：
  
  543001 广西梧州，广西梧州市工人医院(广西医科大学第七附属医院)肿瘤科
- 作者简介：
- 基金信息：
  
  the Project of Medical and Health Sci & Tech Development Center of Health and Family Planning Commission of China(W2015PM010)
- DOI：10.16016/j.1000-5404.201801020
  CLC： R730.53;R734.2;R979.1
- Received：03 January 2018，
  
  Revised：2018-03-29，
  
  Published：15 July 2018
- 稿件说明：
移动端阅览
Yi ZHOU, Jian ZHOU, Ying ZHANG, et al. Clinical efficacy and safety of pemetrexed and nedaplatin in treatment of advanced lung adenocarcinoma[J]. Journal of Third Military Medical University, 2018, 40(13): 1236-1241.
DOI：

Yi ZHOU, Jian ZHOU, Ying ZHANG, et al. Clinical efficacy and safety of pemetrexed and nedaplatin in treatment of advanced lung adenocarcinoma[J]. Journal of Third Military Medical University, 2018, 40(13): 1236-1241. DOI： 10.16016/j.1000-5404.201801020.

摘要

目的

探讨培美曲塞联合奈达铂治疗晚期肺腺癌临床疗效及安全性。

方法

选择2015年4月至2017年12月本科收治的晚期肺腺癌患者，按照随机数字法分成对照组和观察组。观察组使用培美曲塞联合奈达铂方案治疗，对照组使用培美曲塞联合顺铂方案治疗。剔除失访病例后，共有60例患者完成本实验，观察组31例，对照组29例。对比两组患者的临床疗效及随访结果、药物毒副作用、体力状况变化、PS标准评分及生活质量评分。

结果

① 临床疗效及患者随访结果：对照组总有效率为37.93%；观察组总有效率为41.94%，观察组及对照组有效率比较差异无统计学意义(χ

=0.073，

=0.735)；两组中位无进展生存期及1年生存率比较，差异无统计学意义(

0.05)。②化疗药物毒副作用：在白细胞减少的发生率上观察组Ⅲ度以上患者显著比对照组低(

＜0.05)。观察组Ⅱ度以上恶心、呕吐发生率显著比对照组低(

＜0.05)。③2组治疗前后变化PS评分比较及肿瘤患者的生活质量(quality of life

QOL)评分比较差异无统计学意义(

0.05)。④治疗前后EORTC QLQ-C30评价比较：经过化学药物治疗之后，观察组患者总体的健康状态及一般情况(如困倦乏力、恶心、呕吐等)均明显优于对照组(

＜0.05)。

结论

培美曲塞联合奈达铂方案与培美曲塞联合顺铂方案的临床疗效在晚期肺腺癌的治疗中无明显差异，但前者副作用小，安全性高，培美曲塞联合奈达铂化疗方案在针对晚期肺腺癌的治疗上值得推广。

Abstract

Objective

To investigate clinical efficacy and safety of pemetrexed combined with nedaplatin in the treatment of advanced lung adenocarcinoma.

Methods

All patients with advanced lung adenocarcinoma treated in our hospital from April 2015 to April 2017 were recruited in this study. They were randomly divided into control group (pemetrexed combined with cisplatin) and observation group (pemetrexed combined with nedaplatin). After the patients lost in follow-up were eliminated

there were 60 patients finally subjected in this study

including 31 in the observation group and 29 in the control. The clinical efficacy

clinical outcome

toxic and side effects of chemical drugs

change of physical condition

performance status (PS

Zubrod-ECOG-WHO score)

and quality of life (QOL) were separately evaluated in the 2 groups after treatment.

Results

① Clinical efficacy and outcomes: There were no significant differences in overall response rate (37.93%

41.94%

Chi

-square=0.072 0

=0.788 5)

median progression free survival (mPFS) or 1-year survival rate (

0.05) between the control and observation groups. ② Toxic and side effects of chemical drugs: The incidence rate of over grade Ⅲ leukocytopenia was significantly lower in the observation group than the control (9.68%

27.59%

Chi

-square=4.251 2

=0.034 0). And the former group also had lower incidence rate of over grade Ⅱ nausea and vomiting (

0.05). ③ No significant differences were seen in PS score and QOL score in the both groups before and after the treatment (

0.05). ④ Evaluation an

d comparison of EORTC QLQ-C30 before and after treatment: though the QOL of the 2 groups were declined after the treatment of chemical drugs

but the total health and general situation (mental state

fatigue

nausea and vomiting) were significantly better in the observation group than the control group (

0.05).

Conclusion

Though there are no significant differences in clinical efficacy between pemetrexed combined with nedaplatin and with cisplatin in the treatment of advanced lung adenocarcinoma

and the former regimen has the advantages of milder side effects

higher safety and little impact on the QOL of patients. Therefore

it is worthy of popularizing widely in the treatment.

关键词

Keywords

references

凌华晃, 李涛, 吴祥成, 等.培美曲塞二钠联合奈达铂治疗老年晚期肺腺癌的临床疗效及安全性观察[J].中国全科医学, 2013, 16(21):2506-2508.

LING H H, LI T, WU X C, et al. Clinical observation of pemetrexed combined with nedaplatin in the treatment of elderly patients with advanced lung adenocacinoma[J]. Chin Gen Prac, 2013, 16(21):2506-2508.

SMITH A B, COCKS K, PARRY D, et al. Reporting of health-related quality of life (HRQOL) data in oncology trials: a comparison of the European Organization for Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) and the Functional Assessment of Cancer Therapy- General (FACT-G)[J]. Qual Life Res, 2014, 23(3): 971-976. DOI:10.1007/s11136-013-0534-2.

邓坦, 段华新.多西他赛联合奈达铂诱导化疗治疗局部晚期头颈部鳞癌的效果和不良反应观察[J].中国综合临床, 2016, 32(12):1100-1102.

DENG T, DUAN H X. Observation of effect and adverse reaction of docetaxal plus nedaplatin induction chemotherapy for local advanced head and neck squamous cell carcinoma[J]. Clin Med Chin, 2016, 32(12):1100-1102.

PATEL J D, SOCINSKI M A, GARON E B, et al. Pointbreak: a randomized phase Ⅲ study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage ⅢB or Ⅳ nonsquamous non-small-cell lung cancer[J]. J Clin Oncol, 2013, 31(34): 4349-4357. DOI:10.1200/JCO.2012.47.9626.

余建云, 李林均, 陈萍.紫杉醇脂质体联合奈达铂同步放疗在中晚期宫颈癌中的临床研究[J].临床肿瘤学杂志, 2014, 19(10):929-931.

YU J Y, LI L J, CHEN P. Clinical study of paclitaxel liposome and nedaplatin combined with radiotherapy in advanced cervical cancer[J]. Chin Clin Oncol, 2014, 19(10):929-931.

CHEN W, FENG L, NIE H, et al. Andrographolide induces autophagic cell death in human liver cancer cells through cyclophilin D-mediated mitochondrial permeability transition pore[J]. Carcinogenesis, 2012, 33(11): 2190-2198. DOI:10.1093/carcin/bgs264.

ARAVIND A, VARGHESE S H, VEERANARAYANAN S, et al. Aptamer-labeled PLGA nanoparticles for targeting cancer cells[J]. Cancer Nanotechnol, 2012, 3(1/6): 1-12. DOI:10.1007/s12645-011-0024-6.

李函阳, 方鹤, 南钰, 等.培美曲塞或吉西他滨联合奈达铂治疗晚期肺腺癌的近期疗效及安全性[J].中国老年学杂志, 2015, 35(9):2433-2435.

LI H Y, FANG H, NAN Y, et al. The efficacy and safety of pemetrexed or gemcitabine combined with nedaplatin in the treatment of advanced lung adenocarcinoma[J]. Chin J Gerontol, 2015, 35(9):2433-2435.

段惠洁, 顾国民, 王秀丽, 等.培美曲塞联合奈达铂一线方案治疗晚期肺腺癌的临床研究[J].肿瘤防治研究, 2014, 41(1):61-64.

DUAN H J, GU G M, WANG X L, et al. Clinical curative effects of pemetrexed plus nedaplatin as first-line treatment in patients with advanced lung adenocarcinoma[J]. Cancer Res Prev Treat, 2014, 41(1):61-64.

吴强.奈达铂或顺铂同期放化疗治疗局部晚期鼻咽癌的不良反应及对生活质量的影响[J].医学理论与实践, 2015, 28(11):1496-1497.

WU Q. Effect of concurrent chemotherapy with nedaplatin or cisplatin on locally advanced nasopharyngeal carcinoma and its influence on quality of life[J]. J Med Theory Prac, 2015, 28(11):1496-1497.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Efficiency and toxic reaction of nedaplatin combined with gemcitabine or paclitaxel in treatment of advanced non-small cell lung cancer: report of 133 cases

Induction chemotherapy efficacy and toxicity of nedaplatin combined tegafur for locally advanced nasopharyngeal carcinoma

Effect of 5-aza-2-deoxycytidine and trichostatin A on proliferation and apoptosis of lung epithelial carcinoma A549 cells

SOCS3 gene inhibits the growth of A549 cell transplantation tumor in nude mice

Related Author

邵克锐

王建春

李莎莎

胡义德

董必文

段凤英

段训凰

余祖滨

Related Institution

No data

⁰